Sanofi/GSK Coronavirus Vaccine Candidate Fails To Produce Sufficient Immune Response In Older People, Delaying Trials
Reuters: Sanofi and GSK delay COVID-19 vaccine, marking setback for global fight
“Sanofi and GlaxoSmithKline said clinical trials of their COVID-19 vaccine showed an insufficient immune response in older people, delaying its launch to late next year and marking a setback in the global fight against the pandemic. … The news, which came on the same day as Australia axed a domestic vaccine project, is also a blow for many governments that have booked hundreds of millions of doses of the shot, including the European Union, United States, and Britain. … The two companies said they planned to start another study next February, hoping to come up with a more effective vaccine by the end of 2021…” (Blamont et al., 12/11).
Additional coverage of the Sanofi/GSK vaccine candidate is available from Financial Times.